Robert Martell's most recent trade in Indaptus Therapeutics Inc was a trade of 12,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Indaptus Therapeutics Inc | Robert E. Martell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Indaptus Therapeutics Inc | Robert E. Martell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Indaptus Therapeutics Inc | Robert E. Martell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Curis Inc | Robert E. Martell | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 350,000 | 350,000 | - | - | Employee stock option (right to buy) | |
| Curis Inc | Robert E. Martell | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2022 | 252,000 | 252,000 | - | - | Employee stock option (right to buy) | |
| Curis Inc | Robert Martell | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 126,000 | 126,000 | - | - | Employee stock option (right to buy) |